Posted by Michael Wonder on 12 Oct 2022
FDA authorises Moderna and Pfizer-BioNTech bivalent COVID-19 vaccines for use as a booster dose in younger age groups
12 October 2022 - Today, the US FDA amended the emergency use authorisations of the Moderna COVID-19 Vaccine, Bivalent and the Pfizer-BioNTech COVID-19 Vaccine, Bivalent to authorise their use as a single booster dose in younger age groups.
The Moderna COVID-19 Vaccine, Bivalent is authorised for administration at least two months following completion of primary or booster vaccination in children down to six years of age.
The Pfizer-BioNTech COVID-19 Vaccine, Bivalent is authorised for administration at least two months following completion of primary or booster vaccination in children down to five years of age.
